Advanced drug delivery systems targeting metabolic disorders: erythropoietic protoporphyria

Verma, N; Thapa, K; Kanojia, N; Dureja, H; Dua, K

Advanced drug delivery systems targeting metabolic disorders: erythropoietic protoporphyria

Verma, N Thapa, K Kanojia, N Dureja, H Dua, K

Permalink

Publisher:: Elsevier
Publication Type:: Chapter
Citation:: Drug Delivery Systems for Metabolic Disorders, 2022, pp. 85-95
Issue Date:: 2022-01-01

Closed Access

	Filename	Description	Size
	3-s2.0-B9780323996167000244-main.pdf	Published version	482.27 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Verma, N
dc.contributor.author	Thapa, K
dc.contributor.author	Kanojia, N
dc.contributor.author	Dureja, H
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.date.accessioned	2023-02-15T21:00:07Z
dc.date.available	2023-02-15T21:00:07Z
dc.date.issued	2022-01-01
dc.identifier.citation	Drug Delivery Systems for Metabolic Disorders, 2022, pp. 85-95
dc.identifier.isbn	9780323996334
dc.identifier.uri	http://hdl.handle.net/10453/166168
dc.description.abstract	Erythropoietic protoporphyria (EPP) is an inherited condition heme biosynthesis disorder characterized by extreme hepatotoxicity and photosensitivity. Too far, no viable therapies are available. Cimetidine has already been proven to suppress heme production and alleviate symptoms in individuals suffering from porphyria cutanea tarda and acute intermittent porphyria. These sicknesses cause the development of erythrocyte protoporphyrin within the plasma, which would then be able to be drawn basically in the liver and vascular endothelium. Sun exposure activates the stored protoporphyrin, causing singlet oxygen radical interactions that cause tissue injury and agonizing agony. Protoporphyrin accumulation in hepatocytes/or bile causes symptomatic severe liver damage in 2%–5% of individuals, which could progress to cholestatic organ failure necessitating transplantation. Following minutes of sunlight exposure, most individuals develop immediate, acute, non-blistering phototoxicity. Anemia affects around 47 percent of cases, and approximately 27 percent have aberrant serum aminotransferases. The presence of considerably increased erythrocyte protoporphyrin concentrations, with a predominance of metal-free protoporphyrin, is used to detect EPPP and XLP. Genetic testing, which includes sequencing the FECH or ALAS2 genes, confirms the diagnosis. There are presently no FDA-approved treatments for such diseases, therefore therapy is confined to protection from the sun. Afamelanotide, a synthesized counterpart of -melanocyte-stimulating hormone, is shown to raise the standard of living and enhance pain-free sunlight exposure in people with EPP. It was authorized for usage in European Union in 2014, however, it is not currently accessible in the United States. The medication delivery system and therapy of erythropoietic uroporphyria have been discussed in this chapter.
dc.language	en
dc.publisher	Elsevier
dc.relation.ispartof	Drug Delivery Systems for Metabolic Disorders
dc.relation.isbasedon	10.1016/B978-0-323-99616-7.00024-4
dc.rights	info:eu-repo/semantics/closedAccess
dc.title	Advanced drug delivery systems targeting metabolic disorders: erythropoietic protoporphyria
dc.type	Chapter
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Pharmacy
utslib.copyright.status	closed_access	*
dc.date.updated	2023-02-15T21:00:05Z
pubs.publication-status	Published

Abstract:

Erythropoietic protoporphyria (EPP) is an inherited condition heme biosynthesis disorder characterized by extreme hepatotoxicity and photosensitivity. Too far, no viable therapies are available. Cimetidine has already been proven to suppress heme production and alleviate symptoms in individuals suffering from porphyria cutanea tarda and acute intermittent porphyria. These sicknesses cause the development of erythrocyte protoporphyrin within the plasma, which would then be able to be drawn basically in the liver and vascular endothelium. Sun exposure activates the stored protoporphyrin, causing singlet oxygen radical interactions that cause tissue injury and agonizing agony. Protoporphyrin accumulation in hepatocytes/or bile causes symptomatic severe liver damage in 2%–5% of individuals, which could progress to cholestatic organ failure necessitating transplantation. Following minutes of sunlight exposure, most individuals develop immediate, acute, non-blistering phototoxicity. Anemia affects around 47 percent of cases, and approximately 27 percent have aberrant serum aminotransferases. The presence of considerably increased erythrocyte protoporphyrin concentrations, with a predominance of metal-free protoporphyrin, is used to detect EPPP and XLP. Genetic testing, which includes sequencing the FECH or ALAS2 genes, confirms the diagnosis. There are presently no FDA-approved treatments for such diseases, therefore therapy is confined to protection from the sun. Afamelanotide, a synthesized counterpart of -melanocyte-stimulating hormone, is shown to raise the standard of living and enhance pain-free sunlight exposure in people with EPP. It was authorized for usage in European Union in 2014, however, it is not currently accessible in the United States. The medication delivery system and therapy of erythropoietic uroporphyria have been discussed in this chapter.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/166168